ATE287726T1 - Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion - Google Patents
Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktionInfo
- Publication number
- ATE287726T1 ATE287726T1 AT99950431T AT99950431T ATE287726T1 AT E287726 T1 ATE287726 T1 AT E287726T1 AT 99950431 T AT99950431 T AT 99950431T AT 99950431 T AT99950431 T AT 99950431T AT E287726 T1 ATE287726 T1 AT E287726T1
- Authority
- AT
- Austria
- Prior art keywords
- measles
- hepatitis
- production
- measles virus
- vaccine against
- Prior art date
Links
- 241000712079 Measles morbillivirus Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940001442 combination vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 201000005505 Measles Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000005252 hepatitis A Diseases 0.000 abstract 2
- 241000709721 Hepatovirus A Species 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 210000001840 diploid cell Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001902 propagating effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
- C12N2760/18464—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32461—Methods of inactivation or attenuation
- C12N2770/32464—Methods of inactivation or attenuation by serial passage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98124548A CN1062770C (zh) | 1998-11-12 | 1998-11-12 | 甲肝-麻疹二联疫苗及其生产方法 |
| PCT/CN1999/000162 WO2000029018A1 (en) | 1998-11-12 | 1999-10-13 | Combined vaccine against both hav and measle virus and method of producing it |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE287726T1 true ATE287726T1 (de) | 2005-02-15 |
Family
ID=5228699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99950431T ATE287726T1 (de) | 1998-11-12 | 1999-10-13 | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6562350B1 (de) |
| EP (1) | EP1129723B1 (de) |
| KR (1) | KR20010101005A (de) |
| CN (1) | CN1062770C (de) |
| AT (1) | ATE287726T1 (de) |
| AU (1) | AU6323599A (de) |
| DE (1) | DE69923470T2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053590C (zh) * | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
| US8124397B2 (en) * | 2005-08-08 | 2012-02-28 | Oregon Health & Science University | Inactivating pathogens with oxidizing agents for vaccine production |
| MX2009004862A (es) * | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| WO2009014774A1 (en) * | 2007-04-06 | 2009-01-29 | Inviragen, Inc. | Methods and compositions for live attenuated viruses |
| JP5854559B2 (ja) | 2009-07-06 | 2016-02-09 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 小胞を調製する方法及びこれから製造される製剤 |
| CA2803282C (en) | 2009-07-06 | 2018-05-01 | David E. Anderson | Methods for preparing vesicles and formulations produced therefrom |
| EP2646051A4 (de) * | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | Flüssige virale formulierungen |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| US10736844B2 (en) | 2011-01-13 | 2020-08-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| CN102210858B (zh) * | 2011-05-18 | 2013-05-08 | 北京科兴生物制品有限公司 | 一种肠道病毒71型与甲型肝炎联合疫苗 |
| CN102343087A (zh) * | 2011-10-21 | 2012-02-08 | 长春祈健生物制品有限公司 | 麻疹长-47株制备二倍体细胞减毒活疫苗及制备工艺 |
| AU2013208693B2 (en) | 2012-01-12 | 2017-12-07 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| EP2806894A4 (de) | 2012-01-27 | 2015-11-04 | Variation Biotechnologies Inc | Verfahren und zusammensetzungen für therapeutika |
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| EP3103474A1 (de) * | 2015-06-12 | 2016-12-14 | Institut Pasteur | Lebendes rekombinantes masern-m2-virus und dessen verwendung bei auslösung von immunität gegen influenzaviren |
| WO2017056101A1 (en) * | 2015-09-30 | 2017-04-06 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
| CN113218723A (zh) * | 2021-03-16 | 2021-08-06 | 吴敏 | 一种用于显微镜观察的组合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792356C2 (de) * | 1968-08-23 | 1983-03-03 | Behringwerke Ag, 3550 Marburg | Staupe-Kombinationsvaccinen und Verfahren zu ihrer Herstellung |
| FR2633518B1 (fr) * | 1988-06-30 | 1991-03-22 | Merieux Inst | Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues |
| CA2075521C (en) * | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
| CN1029239C (zh) * | 1992-12-29 | 1995-07-05 | 卫生部长春生物制品研究所 | 甲型肝炎疫苗的生产方法 |
| CA2274755A1 (en) * | 1996-12-20 | 1998-07-02 | Su-Pi Sheu | Stabilizers for lyophilized vaccines |
-
1998
- 1998-11-12 CN CN98124548A patent/CN1062770C/zh not_active Expired - Lifetime
-
1999
- 1999-10-13 EP EP19990950431 patent/EP1129723B1/de not_active Expired - Lifetime
- 1999-10-13 KR KR1020017006008A patent/KR20010101005A/ko not_active Ceased
- 1999-10-13 AU AU63235/99A patent/AU6323599A/en not_active Abandoned
- 1999-10-13 US US09/831,752 patent/US6562350B1/en not_active Expired - Fee Related
- 1999-10-13 DE DE1999623470 patent/DE69923470T2/de not_active Expired - Fee Related
- 1999-10-13 AT AT99950431T patent/ATE287726T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU6323599A (en) | 2000-06-05 |
| CN1062770C (zh) | 2001-03-07 |
| CN1217212A (zh) | 1999-05-26 |
| EP1129723B1 (de) | 2005-01-26 |
| DE69923470D1 (de) | 2005-03-03 |
| DE69923470T2 (de) | 2006-03-30 |
| KR20010101005A (ko) | 2001-11-14 |
| EP1129723A4 (de) | 2002-10-24 |
| EP1129723A1 (de) | 2001-09-05 |
| US6562350B1 (en) | 2003-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE287726T1 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
| DK1194580T4 (da) | In-vitro rekonstitution af segmenterede negativstrengede RNA-virus | |
| MY140680A (en) | Hepatitis c virus inhibitors | |
| NO972608L (no) | Opplösningshjelpemidler for hydrofile makromolekyler | |
| CY1110964T1 (el) | Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας | |
| ES2150903T3 (es) | Derivados de 2-aralcoxi y 2-alcoxi adenosina de utilidad como vasodilatadores coronarios y como agentes antihipertensivos. | |
| PT891420E (pt) | Processos para a replicacao dos virus influenza numa cultura celular e os virus influenza que se podem obter atraves do processo | |
| ATE482267T1 (de) | Tierzellen und verfahren für die replikation von influenza viren | |
| BR0309659A (pt) | Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso | |
| PL330407A1 (en) | Substituted cyclopentane compounds useful as neuraminidaze inhibitors | |
| ATE393212T2 (de) | Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen | |
| HUP0000992A2 (hu) | Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai | |
| ATE114713T1 (de) | Biomasse zur produktion von virus/virusantigen. | |
| BR0308736A (pt) | Células de pulmão de rato cotton para cultura de vìrus | |
| DE69428610D1 (de) | Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus | |
| WO2000058444A3 (en) | Adaptation of virus to vertebrate cells | |
| JPS57126423A (en) | Preparation of mixed viral live vaccine | |
| RU96115433A (ru) | Вакцинный штамм вируса кори л-16в, способ его культивирования и живая вакцина для профилактики кори | |
| UA37622A (uk) | 1,5-піперидил - 3,7-біс/діетаноламіну/ - піримідил ізовалеріанат, що використовується для діагностики вірусних інфекцій | |
| ATE4510T1 (de) | Impfstoffe fuer infektioese bronchitis bei gefluegel, kombinierte impfstoffe fuer infektioese bronchitis, verfahren zur herstellung solcher impfstoffe, verfahren zur verhuetung infektioeser bronchitis und virusstaemme der infektioesen bronchitis. | |
| CA2250714A1 (en) | Animal cells and processes for the replication of influenza viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1129723 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |